JP2023085489A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023085489A5 JP2023085489A5 JP2023062141A JP2023062141A JP2023085489A5 JP 2023085489 A5 JP2023085489 A5 JP 2023085489A5 JP 2023062141 A JP2023062141 A JP 2023062141A JP 2023062141 A JP2023062141 A JP 2023062141A JP 2023085489 A5 JP2023085489 A5 JP 2023085489A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20171221.3 | 2020-04-24 | ||
| EP20171221 | 2020-04-24 | ||
| PCT/EP2021/059015 WO2021213800A1 (en) | 2020-04-24 | 2021-04-07 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| JP2022563041A JP7260723B2 (ja) | 2020-04-24 | 2021-04-07 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563041A Division JP7260723B2 (ja) | 2020-04-24 | 2021-04-07 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023085489A JP2023085489A (ja) | 2023-06-20 |
| JP2023085489A5 true JP2023085489A5 (OSRAM) | 2024-04-09 |
Family
ID=70470818
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563041A Active JP7260723B2 (ja) | 2020-04-24 | 2021-04-07 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
| JP2023062141A Pending JP2023085489A (ja) | 2020-04-24 | 2023-04-06 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563041A Active JP7260723B2 (ja) | 2020-04-24 | 2021-04-07 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US11608343B2 (OSRAM) |
| EP (2) | EP4566611A3 (OSRAM) |
| JP (2) | JP7260723B2 (OSRAM) |
| KR (2) | KR20250016507A (OSRAM) |
| CN (13) | CN118388495A (OSRAM) |
| AR (1) | AR121779A1 (OSRAM) |
| AU (1) | AU2021260721A1 (OSRAM) |
| BR (1) | BR112022021514A2 (OSRAM) |
| CA (1) | CA3173602A1 (OSRAM) |
| CL (1) | CL2022002579A1 (OSRAM) |
| CO (1) | CO2022015054A2 (OSRAM) |
| CR (1) | CR20220537A (OSRAM) |
| DK (1) | DK4139309T5 (OSRAM) |
| DO (1) | DOP2022000189A (OSRAM) |
| EC (1) | ECSP22072777A (OSRAM) |
| ES (1) | ES3013860T3 (OSRAM) |
| FI (1) | FI4139309T3 (OSRAM) |
| HR (1) | HRP20250426T1 (OSRAM) |
| HU (1) | HUE070805T2 (OSRAM) |
| IL (2) | IL297490B2 (OSRAM) |
| LT (1) | LT4139309T (OSRAM) |
| MA (1) | MA59373B1 (OSRAM) |
| MX (1) | MX2022013223A (OSRAM) |
| PE (1) | PE20230827A1 (OSRAM) |
| PH (1) | PH12022552745A1 (OSRAM) |
| PL (1) | PL4139309T3 (OSRAM) |
| PT (1) | PT4139309T (OSRAM) |
| RS (1) | RS66557B1 (OSRAM) |
| SI (1) | SI4139309T1 (OSRAM) |
| SM (1) | SMT202500164T1 (OSRAM) |
| TW (1) | TW202206432A (OSRAM) |
| WO (1) | WO2021213800A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787150A (zh) | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| US20230126204A1 (en) * | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022266458A1 (en) * | 2021-06-17 | 2022-12-22 | Black Diamond Therapeutics, Inc. | 6-heterocycloalkyl-quinazoline derivatives and uses thereof |
| WO2022269531A1 (en) | 2021-06-26 | 2022-12-29 | Array Biopharma Inc. | Her2 mutation inhibitors |
| EP4476211A1 (en) * | 2022-02-09 | 2024-12-18 | Enliven Inc. | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 |
| US20250206760A1 (en) | 2022-03-28 | 2025-06-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof |
| CA3267358A1 (en) * | 2022-04-05 | 2025-03-22 | Voronoi Inc | HETEROARYL DERIVATIVE AND ITS USE |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| TW202417458A (zh) | 2022-08-22 | 2024-05-01 | 美商依安彼克醫療有限公司 | 調節her2的化合物及方法 |
| EP4637773A1 (en) | 2022-12-22 | 2025-10-29 | Boehringer Ingelheim International GmbH | Crystalline forms of a her2 inhibitor |
| KR20250123210A (ko) | 2022-12-22 | 2025-08-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Her2 억제제 고체 분산체의 투여 스케줄 |
| TW202440121A (zh) | 2022-12-22 | 2024-10-16 | 德商百靈佳殷格翰國際股份有限公司 | Her2抑制劑之固體分散體 |
| WO2024200637A2 (en) | 2023-03-29 | 2024-10-03 | Boehringer Ingelheim International Gmbh | Dosing schedule of a her2 inhibitor |
| KR20250164828A (ko) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024246114A1 (en) | 2023-05-31 | 2024-12-05 | Boehringer Ingelheim International Gmbh | Survivin as a biomarker for predicting the responsiveness of cancer treatment |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| US20250122206A1 (en) | 2023-07-28 | 2025-04-17 | Boehringer Ingelheim International Gmbh | Process for the manufacture of a her2 inhibitor |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025051693A1 (en) * | 2023-09-06 | 2025-03-13 | Boehringer Ingelheim International Gmbh | Cancer treatment with a her2 inhibitor and a cyp3a and/or p-gp modulator |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025132549A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Cancer combination therapy using zongertinib and a kras g12c inhibitor |
| WO2025132522A1 (en) | 2023-12-20 | 2025-06-26 | Boehringer Ingelheim International Gmbh | Anti-cancer combination therapy |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025210042A1 (en) * | 2024-04-03 | 2025-10-09 | Boehringer Ingelheim International Gmbh | Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW414798B (en) * | 1994-09-07 | 2000-12-11 | Thomae Gmbh Dr K | Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| BR0214499A (pt) | 2001-12-12 | 2005-05-10 | Pfizer Prod Inc | Derivados de quinazolina para o tratamento do crescimento anormal das células |
| JP2007510708A (ja) | 2003-11-06 | 2007-04-26 | ファイザー・プロダクツ・インク | 癌の治療における選択的ｅｒｂＢ２阻害剤／抗ｅｒｂＢ抗体の組合せ |
| PL2090575T3 (pl) | 2005-11-15 | 2011-09-30 | Array Biopharma Inc | Sposoby i związki pośrednie do otrzymywania pochodnych N4-fenylo-chinazolino-4-aminy |
| US20070107957A1 (en) * | 2005-11-16 | 2007-05-17 | Lonnie Lehrer | Automobile propulsion system |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3157916B1 (en) | 2014-06-19 | 2018-12-12 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| US20210323976A1 (en) | 2015-05-13 | 2021-10-21 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN111032655B (zh) | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| JP7333313B2 (ja) | 2017-09-01 | 2023-08-24 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 窒素含有複素環化合物、製造方法、中間体、組成物および使用 |
| CN115052881B (zh) | 2020-02-03 | 2024-07-09 | 勃林格殷格翰国际有限公司 | 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶 |
| US20230126204A1 (en) | 2020-02-03 | 2023-04-27 | Boehringer Ingelheim International Gmbh | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS |
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| WO2021231400A1 (en) * | 2020-05-12 | 2021-11-18 | Accutar Biotechnology, Inc. | Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors |
-
2021
- 2021-04-06 US US17/223,132 patent/US11608343B2/en active Active
- 2021-04-07 SM SM20250164T patent/SMT202500164T1/it unknown
- 2021-04-07 CN CN202410508211.XA patent/CN118388495A/zh active Pending
- 2021-04-07 MX MX2022013223A patent/MX2022013223A/es unknown
- 2021-04-07 LT LTEPPCT/EP2021/059015T patent/LT4139309T/lt unknown
- 2021-04-07 EP EP24221865.9A patent/EP4566611A3/en active Pending
- 2021-04-07 EP EP21716218.9A patent/EP4139309B9/en active Active
- 2021-04-07 ES ES21716218T patent/ES3013860T3/es active Active
- 2021-04-07 KR KR1020257002191A patent/KR20250016507A/ko active Pending
- 2021-04-07 CN CN202410494941.9A patent/CN118388492A/zh active Pending
- 2021-04-07 CN CN202410490491.6A patent/CN118388490A/zh active Pending
- 2021-04-07 MA MA59373A patent/MA59373B1/fr unknown
- 2021-04-07 IL IL297490A patent/IL297490B2/en unknown
- 2021-04-07 CN CN202410479058.2A patent/CN118619956A/zh active Pending
- 2021-04-07 CN CN202410479057.8A patent/CN118388487A/zh active Pending
- 2021-04-07 TW TW110112486A patent/TW202206432A/zh unknown
- 2021-04-07 HU HUE21716218A patent/HUE070805T2/hu unknown
- 2021-04-07 PH PH1/2022/552745A patent/PH12022552745A1/en unknown
- 2021-04-07 IL IL320477A patent/IL320477A/en unknown
- 2021-04-07 CN CN202410475949.0A patent/CN118307544A/zh active Pending
- 2021-04-07 CN CN202410481750.9A patent/CN118388488A/zh active Pending
- 2021-04-07 BR BR112022021514A patent/BR112022021514A2/pt unknown
- 2021-04-07 DK DK21716218.9T patent/DK4139309T5/da active
- 2021-04-07 AU AU2021260721A patent/AU2021260721A1/en active Pending
- 2021-04-07 WO PCT/EP2021/059015 patent/WO2021213800A1/en not_active Ceased
- 2021-04-07 AR ARP210100910A patent/AR121779A1/es unknown
- 2021-04-07 SI SI202130269T patent/SI4139309T1/sl unknown
- 2021-04-07 CN CN202410494942.3A patent/CN118388493A/zh active Pending
- 2021-04-07 CN CN202410508210.5A patent/CN118388494A/zh active Pending
- 2021-04-07 CA CA3173602A patent/CA3173602A1/en active Pending
- 2021-04-07 RS RS20250199A patent/RS66557B1/sr unknown
- 2021-04-07 PT PT217162189T patent/PT4139309T/pt unknown
- 2021-04-07 JP JP2022563041A patent/JP7260723B2/ja active Active
- 2021-04-07 CN CN202410490516.2A patent/CN118388491A/zh active Pending
- 2021-04-07 PE PE2022002443A patent/PE20230827A1/es unknown
- 2021-04-07 FI FIEP21716218.9T patent/FI4139309T3/fi active
- 2021-04-07 CN CN202410475947.1A patent/CN118307543A/zh active Pending
- 2021-04-07 CN CN202410481753.2A patent/CN118388489A/zh active Pending
- 2021-04-07 CN CN202180030549.3A patent/CN115485277B/zh active Active
- 2021-04-07 PL PL21716218.9T patent/PL4139309T3/pl unknown
- 2021-04-07 CR CR20220537A patent/CR20220537A/es unknown
- 2021-04-07 KR KR1020227040861A patent/KR102759974B1/ko active Active
- 2021-04-07 HR HRP20250426TT patent/HRP20250426T1/hr unknown
-
2022
- 2022-09-14 DO DO2022000189A patent/DOP2022000189A/es unknown
- 2022-09-21 EC ECSENADI202272777A patent/ECSP22072777A/es unknown
- 2022-09-23 CL CL2022002579A patent/CL2022002579A1/es unknown
- 2022-10-21 CO CONC2022/0015054A patent/CO2022015054A2/es unknown
-
2023
- 2023-02-10 US US18/167,168 patent/US20230374021A1/en not_active Abandoned
- 2023-04-06 JP JP2023062141A patent/JP2023085489A/ja active Pending
-
2024
- 2024-06-25 US US18/753,429 patent/US20250122204A1/en active Pending